Cutaneous T-Cell Lymphoma
A group of rare non-Hodgkin lymphomas where malignant T lymphocytes accumulate in the skin. Includes mycosis fungoides and Sezary syndrome. Presents with skin patches, plaques, or tumors. Progressive disease can spread to lymph nodes and internal organs.
Quick Answer
What it is
A group of rare non-Hodgkin lymphomas where malignant T lymphocytes accumulate in the skin. Includes mycosis fungoides and Sezary syndrome.
Key findings
- Grade A: Overall Response Rate (CTCL) (Romidepsin (Istodax))
- Grade A: Pruritus Improvement (CTCL) (Romidepsin (Istodax))
Safety
No specific caution or interaction language was detected in the current summary/outcome notes.
ℹ️ Quick Facts
Quick Facts: Cutaneous T-Cell Lymphoma
- Supplements Studied:1
1 supps · 2 outcomes
Detailed Outcomes
A
Overall Response Rate (CTCL)
Two pivotal Phase 2 trials in relapsed/refractory CTCL (n=71, n=96): ORR 34-35% with 6% CR in both studies. Among 68 patients with advanced disease, 38% achieved response including 5 CRs. Led to FDA approval Nov 2009.
moderate↑Improves
A
Pruritus Improvement (CTCL)
43% (28/65) of patients with moderate-severe pruritus at baseline achieved improvement. Important quality of life benefit in CTCL where pruritus is often debilitating.
moderate↓Improves